The Gates Foundation is part of the Grand Challenges partnership network. Visit <a href="https://www.grandchallenges.org" target="_blank">www.grandchallenges.org</a> to view the map of awarded grants across this network and grant opportunities from partners.

Grand Challenges supports exceptional scientists with the expertise to do breakthrough R&amp;D as well as the experience, networks, and skills to excel as scientific leaders. These champions co-create projects with global partners, mobilize key institutions in their countries, and improve public health in their communities and around the world.

Grand Challenges funds innovations to tackle the biggest problems in global health and development. Since 2004, through the Grand Challenges program, we have supported more than 2500 innovation projects in more than 90 countries.

For more than 20 years, Grand Challenges has built trusted relationships with global health funders and researchers. We tap into this powerful network to create unique scientific collaborations with a transformative impact on people's lives.

Innovation happens all along the journey from idea, to experiment, to product or policy, and finally to delivery at scale in communities. We fund innovation projects while supporting an environment of champions, systems, and partnerships to maximize the impact these projects make in people's lives.

The 4 Pillars of the Grand Challenges Ecosystem

Doing groundbreaking science requires the right mix of institutions, policies, and tools. Grand Challenges works with partners in low- and middle-income countries to build or strengthen the capacities they need to succeed in R&amp;D.

Open Grant Opportunities

Professor Abdoulaye Djimdé Named to UN Secretary General's Scientific Advisory Board

<a href="https://gcgh.grandchallenges.org/champion/abdoulaye-djimde" target="_blank">Professor Abdoulaye Djimdé</a> has been appointed to the <a href="https://www.un.org/scientific-advisory-board/en/board-members" target="_blank">United Nations Secretary-General's Scientific Advisory Board</a>, marking an important step in elevating African leaders' voices in global research and science policy conversations.A leading expert in malaria genomics and drug resistance, Prof. Djimdé is focused on building research capacity and scientific collaboration across the continent. He embodies the <a href="https://gcgh.grandchallenges.org/champions" target="_blank">Calestous Juma Science Leadership Fellowship's</a> vision to cultivate scientists who not only drive innovation but also guide decision-making and international cooperation.At a time when the world faces increasingly complex health and development challenges, Prof. Djimdé will bring an important and unique perspective to the board's work on science, technology, and innovation for sustainable development. "Scientific knowledge is strongest when it reflects diverse perspectives," Prof. Djimdé said in response to the appointment, "and I look forward to contributing African experience and expertise to conversations shaping the future of global health and development."

We challenge innovators around the world to work on urgent priorities in global health and development. We issue new challenges regularly and award the most promising proposals with grant funding.&nbsp;

Past Challenges

Grand Challenges South Africa

Innovations in Cost-Disruptive Tools for Diagnosis and Screening

This Grand Challenge seeks cost-disruptive tools for diagnosis and screening, defined as devices that amortize capital to near-zero incremental cost and consumable $1-class tests that materially reset the cost curve in LMICs while meeting real-world deployment constraints. Accordingly, this initiative aims to translate these cost-disruptive concepts into scalable solutions across high-priority disease areas.

This RFP is jointly launched by several Grand Challenges funding partners, including Grand Challenges Africa (Science for Africa Foundation), Grand Challenges Brazil (Brazilian Ministry of Health and the National Council on Research), Grand Challenges India (Biotechnology Industry Research Assistance Council), and Grand Challenges South Africa (South African Medical Research Council). Each RFP may differ in its geographic focus, topic areas, and funding levels. Please review the eligibility criteria and specific requirements for each RFP carefully. The individual RFPs are listed separately <a href="https://gcgh.grandchallenges.org/challenges/JTdCJTIyc29ydCUyMiUzQSUyMmRlc2NlbmRpbmclMjIlMkMlMjJzb3J0RmllbGQlMjIlM0ElMjJkYXRlJTIyJTJDJTIybnVtYmVyUGVyUGFnZSUyMiUzQTEwJTJDJTIycGFnZU51bWJlciUyMiUzQTAlN0Q=/JTdCJTIyeWVhcnMlMjIlM0ElNUIlNUQlMkMlMjJjaGFsbGVuZ2VzJTIyJTNBJTVCJTIyMzk0JTIyJTVEJTJDJTIydGVybXMlMjIlM0ElNUIlNUQlMkMlMjJpbml0aWF0aXZlcyUyMiUzQSU1QiU1RCUyQyUyMmxvY2F0aW9ucyUyMiUzQSU1QiU1RCU3RA==" target="_blank">here</a>. If you qualify for more than one, we encourage you to apply to the RFP that best aligns with your proposed project.Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge, including the Rules and Guidelines, Application Instructions, and Frequently Asked Questions.If you are planning to apply to this RFP, we will be hosting a dedicated webinar on November 20, from 6:00 to 7:00 AM Pacific Time. This session will provide a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance. If you cannot attend live, the webinar will be recorded and available on this challenge page after the session.<h2>Background</h2>Local delivery of drugs into the vagina for prevention and treatment of female-specific conditions remains understudied and under-utilized despite clear potential advantages such as discreetness, potent local efficacy, large surface area for drug absorption, high potential for API dosage sparing, potential for fewer systemic side effects, as well as providing autonomy and empowerment of women. Several key drivers may be responsible for this lag, including paucity of mechanistic biological data, particularly from high-burden settings such as low- and middle-income countries (LMICs), to support the development of specific formulations for vaginal use as well as a persistent misconception that vaginally delivered products may not be embraced by women and their sexual partners. Several of our priorities for impactful products for sexual and reproductive health will require vaginal delivery for immediate, on-demand use. We seek to catalyze the development of innovative technologies and approaches that can safely and effectively deliver a wide range of vaginal products. We expect these approaches to have user appeal, including promotion of self-care capability and other beneficial features that women seek, hence the need to couple discovery research with high-quality end-user input.<h2>The Challenge</h2>We are soliciting applications that contribute to development of vaginal formulations that promote optimal drug delivery within the vaginal compartment while positively supporting the vaginal milieu, and that also possess beneficial effects, even if unrelated to the API intended effect, that a user might consider desirable, such as enhancement of sexual pleasure.We anticipate identifying product-agnostic features that promote vaginal health and that broadly appeal to women to advance product development and formulations for women's health. We welcome innovations at any stage of development that meet the scope of this call.Applicants may apply to address one or more of the following objectives of this challenge:<ol><li>Leverage biology for vaginally administered products: In this objective, we seek: 1) innovative formulations and delivery approaches that leverage the biology of the vaginal microenvironment to support development of novel delivery technologies and that have high potential for scalable, low-cost manufacturing options; and 2) novel components that could be incorporated into and improve existing formulations (e.g. films, tablets/inserts) that would promote maintenance of or transition to an optimal vaginal microbiome and/or promote other benefits to the vaginal mucosal epithelium. Specifically, we seek to assess and de-risk novel approaches to vaginal delivery that can leverage and support features of the vaginal milieu including mucus, host cells and microbes for drug delivery and as such we anticipate proposals including evaluation of the impact of these novel approaches or components on changes in the microbiome and vaginal host components (cells/cytokines, mucins, glycans, lectins, etc.).</li><li>Define characteristics of an ideal vaginal product: In this objective, we seek to support qualitative studies aimed at identifying and understanding specific features of a vaginally administered product that would most appeal to women such that many women, especially those of reproductive age in LMICs, would seek to use such a product (for example, 'what would you hope to achieve when using this product in your vagina?'). We are particularly interested in defining ancillary benefits (such as odor control, sexual enhancement, etc.) that could be derived from a vaginally delivered product that would likely not be supported by other routes of administration, as well as identifying major hurdles that may prevent a woman from seeking out or preferring a vaginal product. We acknowledge that there may be regional, cultural, demographic, or other preference differences, and are seeking to identify desires or barriers that are commonly expressed by women across these demographic differences. Applicants may propose methods to prioritize preferences such that the vaginal product developed can benefit as many women as possible. In sum, we aim to gather insights into preferred and achievable characteristics that would transform vaginal products from 'tolerable' to 'desirable.'</li></ol>Funding LevelProjects with a duration of up to two years and a maximum requested budget of Up to $250,000 USD (~R4.5 million) per project are eligible for funding. Exploratory projects with shorter durations/lower budgets that focus on high-risk, innovative areas are strongly encouraged and will be given priority. Budgets should be commensurate with the scope of work proposed and in line with allowable costs of the targeted funding organization for which the applicant is eligible. Indirect costs should be included in the budget and should not exceed 5% of the total award (subject to the <a href="https://www.samrc.ac.za/sites/default/files/attachments/2024-09/SAMRC%20Terms%20and%20Conditions%20of%20Funding.pdf" target="_blank">SAMRC Terms and Conditions of funding</a>).Eligibility CriteriaThis initiative is open to research institutes, NGOs, academic institutions, government agencies, and for-profit companies, with priority given to women-led projects and collaborations based in low- and middle-income countries (LMICs). Projects must be based in South Africa and led by South African principal investigators, who are citizens or permanent residents. All applicants are expected to comply with the Foundation's global access clause. Applicants are encouraged to build upon existing or complementary projects, studies, or trials, and to engage in collaborations with other institutions. Applications from teams led by women and/or researchers at LMIC-based institutions or involving collaboration with women-led or LMIC-based organizations, are strongly encouraged. Only individuals applying through a legally recognized corporate entity are eligible.We are looking for proposals that:&nbsp;<ul><li>Focus on vaginally delivery approaches that do not require retrieval and disposal after use and can be adapted for extended- or slow-release of active ingredients.</li><li>Use innovative, rigorous qualitative approaches that improve or deepen our understanding of standard acceptability metrics.</li><li>Generate biological or end-user data from low- and middle-income regions and comply with national regulations on data security, data protection, and privacy.</li><li>Propose rigorous scientific approaches to study a clear research question and whose rationale is clearly supported by peer-reviewed literature.</li><li>Demonstrate feasibility with preliminary data in support of the proposed approach; if no preliminary data exists then the proposal should be limited in scope.</li><li>Request the appropriate funds and time to achieve the objectives of the proposed work. Exploratory projects of lower cost but higher risk are strongly encouraged and will be prioritized.</li><li>Promote a diverse, inclusive, and supportive research environment, with priority for collaborations involving LMIC-based experts in reproductive health.</li></ul>We will not fund proposals that:&nbsp;<ul><li>Evaluate the impact of currently available vaginally inserted products on the vaginal milieu (e.g., menstrual products, contraceptive devices, over-the-counter probiotics, etc.).</li><li>Focus on approaches that would not be feasible or affordable in low- and middle-income countries, including personalized medicine. If these approaches are included, the feasibility of scalable, low-cost development should be explicitly stated.</li><li>Focus on the development of therapeutics or interventions for specific conditions, such as treatment for STIs or contraceptive products. While these types of interventions may be used as a test case within the proposal, the work itself should focus on formulations.</li><li>Are focused solely on basic exploratory scientific research without a clear translational pathway, including potential end-use scenarios, scalability considerations and regulatory or manufacturing implications.</li><li>Center solely on focus groups and interviews. These methods or qualitative approaches are acceptable if embedded within rigorous mixed-methods study designs that generate quantitative, actionable insights beyond anecdotal data or standard acceptability metrics such as affective attitudes.</li><li>Do not consider end user preferences or assume end-user preferences. For the purposes of this RFP, end-users can be defined as women of reproductive age in low- and middle-income countries. Proposals may focus on subgroups (e.g., adolescents, post-partum women), but the target group must be explicitly defined and justified.</li><li>Primarily depend on traditional acceptability questionnaires or surveys (e.g., "if x hypothetical product existed, how interested would you be in using it?").</li><li>Do not directly address one of the core objectives as outlined above.</li><li>Can not be accomplished within a two-year maximum project duration or within the stipulated budget maximum.</li><li>Support researchers or research teams who are affiliated with the tobacco industry, or who receive (or are applying for) funding from the tobacco industry, which includes manufacturers and distributors of e-cigarettes or vaping products.</li></ul>Application SubmissionAll applications must be submitted directly through the Grand Challenges South Africa online portal (RedCap): <a href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsamrc-redcap.mrc.ac.za%2Fsurveys%2F%3Fs%3DK9EL9FLPFXJEHJHL&amp;data=05%7C02%7CKarabo.Kgomo%40mrc.ac.za%7C1866ef4376b6441f44d208de1525c6d5%7Cf1930bff9b514d0cb2bdc26a9e0f4600%7C0%7C0%7C638971449165598983%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=b3jIENZek4Ggub2jN7RmCexuWNYTnOmhRVwXXzZc8AU%3D&amp;reserved=0" target="_blank">GCSA Women's Health Innovation Call</a>. (Submissions via email or any other method will not be accepted).Applicants are required to complete the following within the portal:<ol><li>Project Proposal – Complete all registration fields, including the Applicant Profile.</li><li>Uploads – Applicants must provide the following documents:<ul><li>Full Proposal –<a href="https://www.samrc.ac.za/sites/default/files/attachments/2025-10/GCSA%20Vaginal%20Formulations%20Proposal%20Template%202025.docx" target="_blank">Proposal Template</a> (Signed by the institution)</li><li>Budget – Upload as a Microsoft Excel or PDF file using the <a href="https://www.samrc.ac.za/sites/default/files/attachments/2025-10/SAMRC%20Project%20Budget%20Template.xlsx" target="_blank">official budget template</a>. provided in the RFP.</li><li>Curriculum Vitae (CVs) – Upload CVs for the Principal Investigator and all Co-investigators.</li></ul></li></ol>Submission Requirements:<ul><li>Proposals must comply with all formatting and file size limits specified in the RFA.</li><li>Applications must be complete, responsive, and submitted by the deadline.</li><li>Applicants must meet all SAMRC eligibility criteria (e.g., South African PIs, citizens, or permanent residents).</li></ul>For questions regarding the RFP, selection criteria, or application instructions, applicants can contact Karabo Kgomo | SAMRC <a href="mailto:Karabo.Kgomo@mrc.ac.za">Karabo.Kgomo@mrc.ac.za</a> ) for South Africa–specific guidance.Budget Guidelines<ul><li>Budgets submitted must include all applicable taxes.</li><li>South African applicants must prepare budgets in South African Rands (ZAR).</li><li>Applicants from other eligible countries may prepare their budgets in South African Rand or USD, noting that the exchange rate for awards will be based on the USD/ZAR rate at which the SAMRC received the funds.</li><li>All direct line items must be auditable.</li></ul>Allowable costs:<ul><li>Personnel: Soft-funded posts for individuals working on the project (e.g., post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided, and they are not already funded by other means.</li><li>Consultants: Local and/or foreign consultants providing a service or capability not available among project partners but essential for the completion of project deliverables.</li><li>Equipment: Partial or full support for the cost of equipment directly required for the project. Budget limitations may apply.</li><li>Supplies, consumables, and other direct laboratory or research costs.</li><li>Sub-contracts: Any local or international organization providing essential services or capabilities not available among project partners.</li><li>Travel and accommodation directly related to the project's execution.</li><li>Institutional overhead: An indirect cost rate of 5% is allowed.</li></ul>Non-Allowable Costs:<ul><li>Salaries of permanent or fixed-term staff, e.g., tenured staff, professors, etc. That is fully covered by the host institutions.</li><li>Purchase or construction of buildings.</li><li>Rental costs for space owned by the institutions participating in the project.</li><li>Recruitment or retrenchment costs for staff.</li><li>Purchase of office furniture.</li></ul>Review and Evaluation of ProposalsEligibility Screening:<ul><li>All applications will be screened by the SAMRC and Grand Challenges funding partners for completeness and responsiveness to the call and its administrative requirements/provisions.</li><li>Incomplete or non-responsive applications, or those submitted after the deadline, will not be processed further.</li></ul>Evaluation: All eligible applications will be reviewed by local and international experts, considering at least the following criteria:<ul><li>Significance / Relevance / Impact: Potential impact on public health outcomes.</li><li>Approach: Innovation, rationale, work plan, and cost-effectiveness.</li><li>Team: Size, reach, experience, and complementarity of project partners.</li><li>Environment: Availability of infrastructure, equipment, and resources; unique features of the project environment, subject populations, or collaborative arrangements.</li></ul>Timeline<table class="table"><thead><tr><th>Milestone</th><th>Date</th></tr></thead><tbody><tr><td>RFP Launch</td><td>Tuesday, 28 October 2025</td></tr><tr><td>Application Close</td><td>Tuesday, 16 December 2025, 8:30 p.m. SAST</td></tr><tr><td>Review &amp; Approvals</td><td>Jan – March 2026</td></tr><tr><td>Notification of Awards</td><td>April 2026</td></tr><tr><td>Anticipated Project Start</td><td>April/May 2026</td></tr></tbody></table>Additional Information<ul><li>Ethics and regulatory approvals must be obtained before disbursement.</li><li>Funders may verify information provided by applicants.</li><li>No responsibility for costs incurred in preparing applications.</li><li>Funders may amend or withdraw the RFP at any time.</li><li>Successful applicants may be asked to address reviewer comments or negotiate budgets.</li></ul>Contact for queries: Karabo Kgomo | SAMRC <a href="mailto:Karabo.Kgomo@mrc.ac.za">Karabo.Kgomo@mrc.ac.za</a>

Accelerating Innovation in Vaginal Formulations in Support of Women's Health

This RFP is jointly launched by several Grand Challenges funding partners, including Grand Challenges Africa (Science for Africa Foundation), Grand Challenges Brazil (Brazilian Ministry of Health and the National Council on Research), Grand Challenges India (Biotechnology Industry Research Assistance Council), and Grand Challenges South Africa (South African Medical Research Council). Each RFP may differ in its geographic focus, topic areas, and funding levels. Please review the eligibility criteria and specific requirements for each RFP carefully. The individual RFPs are listed separately <a href="https://gcgh.grandchallenges.org/challenges/JTdCJTIyc29ydCUyMiUzQSUyMmRlc2NlbmRpbmclMjIlMkMlMjJzb3J0RmllbGQlMjIlM0ElMjJkYXRlJTIyJTJDJTIybnVtYmVyUGVyUGFnZSUyMiUzQTEwJTJDJTIycGFnZU51bWJlciUyMiUzQTAlN0Q=/JTdCJTIyeWVhcnMlMjIlM0ElNUIlNUQlMkMlMjJjaGFsbGVuZ2VzJTIyJTNBJTVCJTIyMzk0JTIyJTVEJTJDJTIydGVybXMlMjIlM0ElNUIlNUQlMkMlMjJpbml0aWF0aXZlcyUyMiUzQSU1QiU1RCUyQyUyMmxvY2F0aW9ucyUyMiUzQSU1QiU1RCU3RA==" target="_blank" rel="noopener noreferrer">here</a>. If you qualify for more than one, we encourage you to apply to the RFP that best aligns with your proposed project.
Before applying, applicants should familiarize themselves with the supporting documents for this Grand Challenge, including the Rules and Guidelines, Application Instructions, and Frequently Asked Questions.
If you are planning to apply to this RFP, we will be hosting a dedicated webinar on November 20, from 6:00 to 7:00 AM Pacific Time. This session will provide a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance. If you cannot attend live, the webinar will be recorded and available on this challenge page after the session.
<h2>Background</h2>
Local delivery of drugs into the vagina for prevention and treatment of female-specific conditions remains understudied and under-utilized despite clear potential advantages such as discreetness, potent local efficacy, large surface area for drug absorption, high potential for API dosage sparing, potential for fewer systemic side effects, as well as providing autonomy and empowerment of women. Several key drivers may be responsible for this lag, including paucity of mechanistic biological data, particularly from high-burden settings such as low- and middle-income countries (LMICs), to support the development of specific formulations for vaginal use as well as a persistent misconception that vaginally delivered products may not be embraced by women and their sexual partners. Several of our priorities for impactful products for sexual and reproductive health will require vaginal delivery for immediate, on-demand use. We seek to catalyze the development of innovative technologies and approaches that can safely and effectively deliver a wide range of vaginal products. We expect these approaches to have user appeal, including promotion of self-care capability and other beneficial features that women seek, hence the need to couple discovery research with high-quality end-user input.
<h2>The Challenge</h2>
We are soliciting applications that contribute to development of vaginal formulations that promote optimal drug delivery within the vaginal compartment while positively supporting the vaginal milieu, and that also possess beneficial effects, even if unrelated to the API intended effect, that a user might consider desirable, such as enhancement of sexual pleasure.We anticipate identifying product-agnostic features that promote vaginal health and that broadly appeal to women to advance product development and formulations for women's health. We welcome innovations at any stage of development that meet the scope of this call.
Applicants may apply to address one or more of the following objectives of this challenge:
<ol>
<li>Leverage biology for vaginally administered products: In this objective, we seek: 1) innovative formulations and delivery approaches that leverage the biology of the vaginal microenvironment to support development of novel delivery technologies and that have high potential for scalable, low-cost manufacturing options; and 2) novel components that could be incorporated into and improve existing formulations (e.g. films, tablets/inserts) that would promote maintenance of or transition to an optimal vaginal microbiome and/or promote other benefits to the vaginal mucosal epithelium. Specifically, we seek to assess and de-risk novel approaches to vaginal delivery that can leverage and support features of the vaginal milieu including mucus, host cells and microbes for drug delivery and as such we anticipate proposals including evaluation of the impact of these novel approaches or components on changes in the microbiome and vaginal host components (cells/cytokines, mucins, glycans, lectins, etc.).</li>
<li>Define characteristics of an ideal vaginal product: In this objective, we seek to support qualitative studies aimed at identifying and understanding specific features of a vaginally administered product that would most appeal to women such that many women, especially those of reproductive age in LMICs, would seek to use such a product (for example, 'what would you hope to achieve when using this product in your vagina?'). We are particularly interested in defining ancillary benefits (such as odor control, sexual enhancement, etc.) that could be derived from a vaginally delivered product that would likely not be supported by other routes of administration, as well as identifying major hurdles that may prevent a woman from seeking out or preferring a vaginal product. We acknowledge that there may be regional, cultural, demographic, or other preference differences, and are seeking to identify desires or barriers that are commonly expressed by women across these demographic differences. Applicants may propose methods to prioritize preferences such that the vaginal product developed can benefit as many women as possible. In sum, we aim to gather insights into preferred and achievable characteristics that would transform vaginal products from 'tolerable' to 'desirable.'</li>
</ol>
Funding Level
Projects with a duration of up to two years and a maximum requested budget of Up to $250,000 USD (~R4.5 million) per project are eligible for funding. Exploratory projects with shorter durations/lower budgets that focus on high-risk, innovative areas are strongly encouraged and will be given priority. Budgets should be commensurate with the scope of work proposed and in line with allowable costs of the targeted funding organization for which the applicant is eligible. Indirect costs should be included in the budget and should not exceed 5% of the total award (subject to the <a href="https://www.samrc.ac.za/sites/default/files/attachments/2024-09/SAMRC%20Terms%20and%20Conditions%20of%20Funding.pdf" target="_blank" rel="noopener noreferrer">SAMRC Terms and Conditions of funding</a>).
Eligibility Criteria
This initiative is open to research institutes, NGOs, academic institutions, government agencies, and for-profit companies, with priority given to women-led projects and collaborations based in low- and middle-income countries (LMICs). Projects must be based in South Africa and led by South African principal investigators, who are citizens or permanent residents. All applicants are expected to comply with the Foundation's global access clause. Applicants are encouraged to build upon existing or complementary projects, studies, or trials, and to engage in collaborations with other institutions. Applications from teams led by women and/or researchers at LMIC-based institutions or involving collaboration with women-led or LMIC-based organizations, are strongly encouraged. Only individuals applying through a legally recognized corporate entity are eligible.
We are looking for proposals that:&nbsp;
<ul>
<li>Focus on vaginally delivery approaches that do not require retrieval and disposal after use and can be adapted for extended- or slow-release of active ingredients.</li>
<li>Use innovative, rigorous qualitative approaches that improve or deepen our understanding of standard acceptability metrics.</li>
<li>Generate biological or end-user data from low- and middle-income regions and comply with national regulations on data security, data protection, and privacy.</li>
<li>Propose rigorous scientific approaches to study a clear research question and whose rationale is clearly supported by peer-reviewed literature.</li>
<li>Demonstrate feasibility with preliminary data in support of the proposed approach; if no preliminary data exists then the proposal should be limited in scope.</li>
<li>Request the appropriate funds and time to achieve the objectives of the proposed work. Exploratory projects of lower cost but higher risk are strongly encouraged and will be prioritized.</li>
<li>Promote a diverse, inclusive, and supportive research environment, with priority for collaborations involving LMIC-based experts in reproductive health.</li>
</ul>
We will not fund proposals that:&nbsp;
<ul>
<li>Evaluate the impact of currently available vaginally inserted products on the vaginal milieu (e.g., menstrual products, contraceptive devices, over-the-counter probiotics, etc.).</li>
<li>Focus on approaches that would not be feasible or affordable in low- and middle-income countries, including personalized medicine. If these approaches are included, the feasibility of scalable, low-cost development should be explicitly stated.</li>
<li>Focus on the development of therapeutics or interventions for specific conditions, such as treatment for STIs or contraceptive products. While these types of interventions may be used as a test case within the proposal, the work itself should focus on formulations.</li>
<li>Are focused solely on basic exploratory scientific research without a clear translational pathway, including potential end-use scenarios, scalability considerations and regulatory or manufacturing implications.</li>
<li>Center solely on focus groups and interviews. These methods or qualitative approaches are acceptable if embedded within rigorous mixed-methods study designs that generate quantitative, actionable insights beyond anecdotal data or standard acceptability metrics such as affective attitudes.</li>
<li>Do not consider end user preferences or assume end-user preferences. For the purposes of this RFP, end-users can be defined as women of reproductive age in low- and middle-income countries. Proposals may focus on subgroups (e.g., adolescents, post-partum women), but the target group must be explicitly defined and justified.</li>
<li>Primarily depend on traditional acceptability questionnaires or surveys (e.g., "if x hypothetical product existed, how interested would you be in using it?").</li>
<li>Do not directly address one of the core objectives as outlined above.</li>
<li>Can not be accomplished within a two-year maximum project duration or within the stipulated budget maximum.</li>
<li>Support researchers or research teams who are affiliated with the tobacco industry, or who receive (or are applying for) funding from the tobacco industry, which includes manufacturers and distributors of e-cigarettes or vaping products.</li>
</ul>
Application Submission
All applications must be submitted directly through the Grand Challenges South Africa online portal (RedCap): <a href="https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsamrc-redcap.mrc.ac.za%2Fsurveys%2F%3Fs%3DK9EL9FLPFXJEHJHL&amp;data=05%7C02%7CKarabo.Kgomo%40mrc.ac.za%7C1866ef4376b6441f44d208de1525c6d5%7Cf1930bff9b514d0cb2bdc26a9e0f4600%7C0%7C0%7C638971449165598983%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=b3jIENZek4Ggub2jN7RmCexuWNYTnOmhRVwXXzZc8AU%3D&amp;reserved=0" target="_blank" rel="noopener noreferrer">GCSA Women's Health Innovation Call</a>. (Submissions via email or any other method will not be accepted).
Applicants are required to complete the following within the portal:
<ol>
<li>Project Proposal – Complete all registration fields, including the Applicant Profile.</li>
<li>Uploads – Applicants must provide the following documents:
<ul>
<li>Full Proposal –<a href="https://www.samrc.ac.za/sites/default/files/attachments/2025-10/GCSA%20Vaginal%20Formulations%20Proposal%20Template%202025.docx" target="_blank" rel="noopener noreferrer">Proposal Template</a> (Signed by the institution)</li>
<li>Budget – Upload as a Microsoft Excel or PDF file using the <a href="https://www.samrc.ac.za/sites/default/files/attachments/2025-10/SAMRC%20Project%20Budget%20Template.xlsx" target="_blank" rel="noopener noreferrer">official budget template</a>. provided in the RFP.</li>
<li>Curriculum Vitae (CVs) – Upload CVs for the Principal Investigator and all Co-investigators.</li>
</ul>
</li>
</ol>
Submission Requirements:
<ul>
<li>Proposals must comply with all formatting and file size limits specified in the RFA.</li>
<li>Applications must be complete, responsive, and submitted by the deadline.</li>
<li>Applicants must meet all SAMRC eligibility criteria (e.g., South African PIs, citizens, or permanent residents).</li>
</ul>
For questions regarding the RFP, selection criteria, or application instructions, applicants can contact Karabo Kgomo | SAMRC <a href="mailto:Karabo.Kgomo@mrc.ac.za">Karabo.Kgomo@mrc.ac.za</a> ) for South Africa–specific guidance.
Budget Guidelines
<ul>
<li>Budgets submitted must include all applicable taxes.</li>
<li>South African applicants must prepare budgets in South African Rands (ZAR).</li>
<li>Applicants from other eligible countries may prepare their budgets in South African Rand or USD, noting that the exchange rate for awards will be based on the USD/ZAR rate at which the SAMRC received the funds.</li>
<li>All direct line items must be auditable.</li>
</ul>
Allowable costs:
<ul>
<li>Personnel: Soft-funded posts for individuals working on the project (e.g., post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided, and they are not already funded by other means.</li>
<li>Consultants: Local and/or foreign consultants providing a service or capability not available among project partners but essential for the completion of project deliverables.</li>
<li>Equipment: Partial or full support for the cost of equipment directly required for the project. Budget limitations may apply.</li>
<li>Supplies, consumables, and other direct laboratory or research costs.</li>
<li>Sub-contracts: Any local or international organization providing essential services or capabilities not available among project partners.</li>
<li>Travel and accommodation directly related to the project's execution.</li>
<li>Institutional overhead: An indirect cost rate of 5% is allowed.</li>
</ul>
Non-Allowable Costs:
<ul>
<li>Salaries of permanent or fixed-term staff, e.g., tenured staff, professors, etc. That is fully covered by the host institutions.</li>
<li>Purchase or construction of buildings.</li>
<li>Rental costs for space owned by the institutions participating in the project.</li>
<li>Recruitment or retrenchment costs for staff.</li>
<li>Purchase of office furniture.</li>
</ul>
Review and Evaluation of Proposals
Eligibility Screening:
<ul>
<li>All applications will be screened by the SAMRC and Grand Challenges funding partners for completeness and responsiveness to the call and its administrative requirements/provisions.</li>
<li>Incomplete or non-responsive applications, or those submitted after the deadline, will not be processed further.</li>
</ul>
Evaluation: All eligible applications will be reviewed by local and international experts, considering at least the following criteria:
<ul>
<li>Significance / Relevance / Impact: Potential impact on public health outcomes.</li>
<li>Approach: Innovation, rationale, work plan, and cost-effectiveness.</li>
<li>Team: Size, reach, experience, and complementarity of project partners.</li>
<li>Environment: Availability of infrastructure, equipment, and resources; unique features of the project environment, subject populations, or collaborative arrangements.</li>
</ul>
Timeline
<div class="responsive-table"><table>
<thead>
<tr>
<th>Milestone</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFP Launch</td>
<td>Tuesday, 28 October 2025</td>
</tr>
<tr>
<td>Application Close</td>
<td>Tuesday, 16 December 2025, 8:30 p.m. SAST</td>
</tr>
<tr>
<td>Review &amp; Approvals</td>
<td>Jan – March 2026</td>
</tr>
<tr>
<td>Notification of Awards</td>
<td>April 2026</td>
</tr>
<tr>
<td>Anticipated Project Start</td>
<td>April/May 2026</td>
</tr>
</tbody>
</table></div>
Additional Information
<ul>
<li>Ethics and regulatory approvals must be obtained before disbursement.</li>
<li>Funders may verify information provided by applicants.</li>
<li>No responsibility for costs incurred in preparing applications.</li>
<li>Funders may amend or withdraw the RFP at any time.</li>
<li>Successful applicants may be asked to address reviewer comments or negotiate budgets.</li>
</ul>
Contact for queries: Karabo Kgomo | SAMRC <a href="mailto:Karabo.Kgomo@mrc.ac.za">Karabo.Kgomo@mrc.ac.za</a>

We are soliciting applications that contribute to development of vaginal formulations that promote optimal drug delivery within the vaginal compartment while positively supporting the vaginal milieu, and that also possess beneficial effects, even if unrelated to the API intended effect, that a user might consider desirable, such as enhancement of sexual pleasure.

Accelerating Innovation in Vaginal Formulations in Support of Womens Health

<h2>Background</h2>Artificial Intelligence (AI) has significant potential to transform healthcare around the world. But as AI technology continues to advance, there is an urgent need to position low- and middle-income countries<a href="#_ftn1" title="" id="_ftnref1" name="_ftnref1">[i]</a> (LMICs) to lead on the design and co-creation of AI-enabled technologies – thereby helping to improve the health and well-being of their women, children, and vulnerable communities. Through this call for proposal, we are emphasizing AI solutions that are locally driven and owned hence more relevant to address the needs of people they intend to serve and more likely to be accepted and used by local communities.Responsible global use of AI entails a safe, equitable, transparent, reliable, and beneficial process that is adhered to with a high level of accountability. As the world rapidly moves to seize AI's opportunities, it is imperative to monitor and mitigate the safety, ethical, equity, and reliability dimensions of AI deployment. This will allow the enormous resilience, creativity, and commitment of researchers, scientists, and policymakers to capture the full capability of AI for lasting good.Grand Challenges (GC) partners including GC Brazil, GC Ethiopia, GC India, GC Senegal, GC South Africa, and GC Africa (pan-African), along with the Bill &amp; Melinda Gates Foundation, the Patrick J. McGovern Foundation, and the Pasteur Network, have jointly discussed the need for an equitable and responsible approach to the use of AI and specifically Large Language Models (LLMs) in LMICs. This call by the various GC partners is a follow-up to the initial call by the Bill &amp; Melinda Gates Foundation representing collaborative steps towards identifying, nurturing, and catalyzing the creativity, energy, and skills that researchers, implementers, governments, and technical partners have demonstrated in solving specific challenges in their countries and regions through LLMs. We are optimistic that this family of related AI RFPs will provide a platform for potentially transformative solutions to improve the lives and conditions for numerous vulnerable communities.Note that this request for proposals is being launched by six Grand Challenges partners: African researchers located in Ethiopia, Senegal, and South Africa, should apply through the corresponding country specific Grand Challenges portal; African researchers located in all other African countries should apply through the Grand Challenges Africa portal; Brazilian researchers located in Brazilian organizations should apply through the Grand Challenges Brazil portal; and Indian researchers located in Indian organizations should apply through the Grand Challenges India portal. Eligible Pasteur Network sites located in Africa should apply through Grand Challenges Africa and Pasteur Network sites located in Brazil should apply through Grand Challenges Brazil. All other eligible Pasteur Network sites (not located in Africa or Brazil) should apply through Grand Challenges Senegal. Please consult the information provided in the subsection referencing geography of interest on the linked partner site to ensure that your application fits the requirements of the RFP you are applying to._______________________________________________________<a href="#_ftnref1" title="" id="_ftn1" name="_ftn1">[i]</a> See <a href="https://data.worldbank.org/country/XO" target="_blank">World Bank – Low Income Countries</a> for definitions.

Grand Challenges South Africa: Catalyzing Equitable Artificial Intelligence (AI) Use to Improve Global Health

<h2>Background</h2>
Artificial Intelligence (AI) has significant potential to transform healthcare around the world. But as AI technology continues to advance, there is an urgent need to position low- and middle-income countries<a href="#_ftn1" title name="_ftnref1" id="_ftnref1">[i]</a> (LMICs) to lead on the design and co-creation of AI-enabled technologies – thereby helping to improve the health and well-being of their women, children, and vulnerable communities. Through this call for proposal, we are emphasizing AI solutions that are locally driven and owned hence more relevant to address the needs of people they intend to serve and more likely to be accepted and used by local communities.
Responsible global use of AI entails a safe, equitable, transparent, reliable, and beneficial process that is adhered to with a high level of accountability. As the world rapidly moves to seize AI's opportunities, it is imperative to monitor and mitigate the safety, ethical, equity, and reliability dimensions of AI deployment. This will allow the enormous resilience, creativity, and commitment of researchers, scientists, and policymakers to capture the full capability of AI for lasting good.
Grand Challenges (GC) partners including GC Brazil, GC Ethiopia, GC India, GC Senegal, GC South Africa, and GC Africa (pan-African), along with the Bill &amp; Melinda Gates Foundation, the Patrick J. McGovern Foundation, and the Pasteur Network, have jointly discussed the need for an equitable and responsible approach to the use of AI and specifically Large Language Models (LLMs) in LMICs. This call by the various GC partners is a follow-up to the initial call by the Bill &amp; Melinda Gates Foundation representing collaborative steps towards identifying, nurturing, and catalyzing the creativity, energy, and skills that researchers, implementers, governments, and technical partners have demonstrated in solving specific challenges in their countries and regions through LLMs. We are optimistic that this family of related AI RFPs will provide a platform for potentially transformative solutions to improve the lives and conditions for numerous vulnerable communities.
Note that this request for proposals is being launched by six Grand Challenges partners: African researchers located in Ethiopia, Senegal, and South Africa, should apply through the corresponding country specific Grand Challenges portal; African researchers located in all other African countries should apply through the Grand Challenges Africa portal; Brazilian researchers located in Brazilian organizations should apply through the Grand Challenges Brazil portal; and Indian researchers located in Indian organizations should apply through the Grand Challenges India portal. Eligible Pasteur Network sites located in Africa should apply through Grand Challenges Africa and Pasteur Network sites located in Brazil should apply through Grand Challenges Brazil. All other eligible Pasteur Network sites (not located in Africa or Brazil) should apply through Grand Challenges Senegal. Please consult the information provided in the subsection referencing geography of interest on the linked partner site to ensure that your application fits the requirements of the RFP you are applying to.
_______________________________________________________
<a href="#_ftnref1" title name="_ftn1" id="_ftn1">[i]</a> See <a href="https://data.worldbank.org/country/XO" target="_blank" rel="noopener noreferrer">World Bank – Low Income Countries</a> for definitions.

Artificial Intelligence (AI) has significant potential to transform healthcare around the world. But as AI technology continues to advance, there is an urgent need to position low- and middle-income countries (LMICs) to lead on the design and co-creation of AI-enabled technologies – thereby helping to improve the health and well-being of their women, children, and vulnerable communities. Through this call for proposal, we are emphasizing AI solutions that are locally driven and owned hence more relevant to address the needs of people they intend to serve and more likely to be accepted and used by local communities.

Grand Challenges South Africa Catalyzing Equitable Artificial Intelligence (AI) Use to Improve Global Health

Appropriate antibiotic use has the power to save lives in the most vulnerable communities, and antimicrobial resistance (AMR) impacts multiple global health priority areas: HIV/AIDS, tuberculosis, maternal and neonatal health, pneumonia, and enteric and diarrheal diseases. It is critical to better understand the prevalence of AMR and its impact on mortality in developing countries so that access to appropriate antibiotics is ensured while inappropriate use of antibiotics is limited. In particular, there is a need to better understand resistance in bacterial infections of newborns and young children – and to this end, understanding what is the prevalence of AMR in the community, how it impacts mortality, and how it impacts health targets. Tackling AMR will require a global, coordinated approach and the linking together of different research communities for new perspectives on the problem.

Note that this request for proposals is being launched on sequential dates by four Grand Challenges partnerships: African researchers located in African organizations should apply through the joint Grand Challenges Africa/Grand Challenges South Africa portal; Brazilian researchers located in Brazilian organizations should apply through the Grand Challenges Brazil portal; and Indian researchers located in Indian organizations should apply through the Grand Challenges India portal.

<h3>What we are looking for:</h3>

We seek new approaches that have the potential to transform public health action on a regional or global scale by identifying and filling gaps in knowledge on the burden of resistance to antibacterial agents – we are not seeking incremental improvements in typical disease surveillance solutions. Specifically, we seek projects that propose innovation in the following areas:

<ul>
	<li>Data sources: Pilot tests of new sources of data, particularly those that would bring together different research communities for new perspectives on the problem</li>
	<li>Analytical methods: Pilot tests of bioinformatics approaches, including those that combine or connect existing databases in novel ways</li>
	<li>Biomarkers: Pilot tests of new biomarkers or combinations of biomarkers that could lead to new understanding of the actionable implications of antimicrobial resistance surveillance data</li>
	<li>Low-cost technologies and products: Exploratory work in developing new technologies and products, including 1) those that specifically target improved infection prevention and control in healthcare settings to reduce reliance on healthcare provider behavior change, and 2) technologies to remove antibiotics from effluents</li>
</ul>

<h3>We will give highest priority to those projects that:</h3>

<ul>
	<li>Pilot test approaches that could be added to existing surveillance platforms, since we are not seeking to create new surveillance platforms</li>
	<li>Incorporate multiple of the areas of innovation listed above</li>
	<li>Could contribute to a portfolio of funded projects that addresses a country’s regional diversity and the diversity of vulnerable populations</li>
	<li>Explain how proposed approaches will be tested so that they have the highest likelihood of being relevant for implementation in the country’s public health system</li>
</ul>

<h3>Examples of what we are looking for:</h3>

<ul>
	<li>Characterizes type examples of the burden of AMR (e.g., exploring the role of AMR in community or hospital sepsis-related mortality, focusing on children)</li>
	<li>Includes data sources that could indirectly reflect AMR burden (e.g., antimicrobial usage patterns or specifically how vaccination against respiratory or diarrheal diseases impacts antimicrobial use)</li>
	<li>Addresses the diversity of vulnerable populations and the different aspects of the AMR burden that might be reflected in urban versus rural settings</li>
	<li>Includes data sources ranging from the level of the individual (e.g., microbiome across body sites) to the community (e.g., public toilets and sanitation systems), while maintaining a focus on gaining new understanding of the actionable consequences of AMR gene flow.</li>
	<li>Includes data sources that could reflect AMR transmission dynamics between communities (e.g., modes of transportation) or within communities over time (e.g., seasonal-related behaviors)</li>
	<li>Provides an ecological perspective, such as a One Health perspective integrating antimicrobial use in livestock or perspectives that can integrate environmental monitoring in the community setting with medical monitoring in the hospital setting – if these perspectives are explicitly linked to human health outcomes and particularly a focus on vulnerable populations</li>
	<li>Leverages opportunities to build in new ways on existing public health interventions or environmental monitoring platforms - and to bring together different research communities</li>
	<li>Contributes to control of infections in healthcare settings: novel techniques and products to control hospital infection rates and break the chain of transmission of bacteria in clinical settings</li>
	<li>Exploratory work into developing low-cost technologies to remove antibiotics and associated chemicals from effluents</li>
</ul>

<h3>We will NOT consider funding for:</h3>

<ul>
	<li>Proposals to develop diagnostic devices and technologies or for drug discovery. Although diagnostic devices and new drugs are potentially critical to AMR solutions, these areas are not unique to AMR challenges and should therefore be advanced more comprehensively against a broader landscape of possible needs and solutions. Thus, while excluded here, they may be part of a future request for proposals.</li>
	<li>Proposals without a clear application to surveillance or facilitating the development of new evidence describing the global burden of AMR</li>
	<li>Proposals seeking to apply existing tools in ways that do not transform our understanding of the global emergence or spread of AMR</li>
	<li>Incremental improvements to conventional solutions or typical disease surveillance. We will not consider local surveillance programs or projects or small improvements in surveillance, e.g., use of mobile data collection, automation of traditional processes, or improving access to existing tools or technologies.</li>
	<li>Proposals that simply expand the availability of primary data without a clear link to informing our understanding of global AMR epidemiology</li>
	<li>Applications proposing basic research</li>
	<li>Ideas not directly relevant to low- and middle-income contexts</li>
	<li>Genomic and other laboratory-based approaches that lack a clear application to AMR surveillance or epidemiology</li>
	<li>Ideas focused on quantifying resistance in animal or livestock populations or in environmental samples without a direct linkage to how data would impact public health practice</li>
	<li>Proposals involving clinical trials in human volunteers or patients (note: use of existing datasets or other outputs from clinical trials may be considered, as long as the proposed approach is feasible within the time and financial envelopes provided).</li>
</ul>

Grand Challenges South Africa: New Approaches to Characterize the Global Burden of Antimicrobial Resistance

Appropriate antibiotic use has the power to save lives in the most vulnerable communities, and antimicrobial resistance (AMR) impacts multiple global health priority areas: HIV/AIDS, tuberculosis, maternal and neonatal health, pneumonia, and enteric and diarrheal diseases. It is critical to better understand the prevalence of AMR and its impact on mortality in developing countries so that access to appropriate antibiotics is ensured while inappropriate use of antibiotics is limited. In particular, there is a need to better understand resistance in bacterial infections of newborns and young children – and to this end, understanding what is the prevalence of AMR in the community, how it impacts mortality, and how it impacts health targets. Tackling AMR will require a global, coordinated approach and the linking together of different research communities for new perspectives on the problem.
Note that this request for proposals is being launched on sequential dates by four Grand Challenges partnerships: African researchers located in African organizations should apply through the joint Grand Challenges Africa/Grand Challenges South Africa portal; Brazilian researchers located in Brazilian organizations should apply through the Grand Challenges Brazil portal; and Indian researchers located in Indian organizations should apply through the Grand Challenges India portal.
<h3>What we are looking for:</h3>
We seek new approaches that have the potential to transform public health action on a regional or global scale by identifying and filling gaps in knowledge on the burden of resistance to antibacterial agents – we are not seeking incremental improvements in typical disease surveillance solutions. Specifically, we seek projects that propose innovation in the following areas:
<ul>
<li>Data sources: Pilot tests of new sources of data, particularly those that would bring together different research communities for new perspectives on the problem</li>
<li>Analytical methods: Pilot tests of bioinformatics approaches, including those that combine or connect existing databases in novel ways</li>
<li>Biomarkers: Pilot tests of new biomarkers or combinations of biomarkers that could lead to new understanding of the actionable implications of antimicrobial resistance surveillance data</li>
<li>Low-cost technologies and products: Exploratory work in developing new technologies and products, including 1) those that specifically target improved infection prevention and control in healthcare settings to reduce reliance on healthcare provider behavior change, and 2) technologies to remove antibiotics from effluents</li>
</ul>
<h3>We will give highest priority to those projects that:</h3>
<ul>
<li>Pilot test approaches that could be added to existing surveillance platforms, since we are not seeking to create new surveillance platforms</li>
<li>Incorporate multiple of the areas of innovation listed above</li>
<li>Could contribute to a portfolio of funded projects that addresses a country’s regional diversity and the diversity of vulnerable populations</li>
<li>Explain how proposed approaches will be tested so that they have the highest likelihood of being relevant for implementation in the country’s public health system</li>
</ul>
<h3>Examples of what we are looking for:</h3>
<ul>
<li>Characterizes type examples of the burden of AMR (e.g., exploring the role of AMR in community or hospital sepsis-related mortality, focusing on children)</li>
<li>Includes data sources that could indirectly reflect AMR burden (e.g., antimicrobial usage patterns or specifically how vaccination against respiratory or diarrheal diseases impacts antimicrobial use)</li>
<li>Addresses the diversity of vulnerable populations and the different aspects of the AMR burden that might be reflected in urban versus rural settings</li>
<li>Includes data sources ranging from the level of the individual (e.g., microbiome across body sites) to the community (e.g., public toilets and sanitation systems), while maintaining a focus on gaining new understanding of the actionable consequences of AMR gene flow.</li>
<li>Includes data sources that could reflect AMR transmission dynamics between communities (e.g., modes of transportation) or within communities over time (e.g., seasonal-related behaviors)</li>
<li>Provides an ecological perspective, such as a One Health perspective integrating antimicrobial use in livestock or perspectives that can integrate environmental monitoring in the community setting with medical monitoring in the hospital setting – if these perspectives are explicitly linked to human health outcomes and particularly a focus on vulnerable populations</li>
<li>Leverages opportunities to build in new ways on existing public health interventions or environmental monitoring platforms - and to bring together different research communities</li>
<li>Contributes to control of infections in healthcare settings: novel techniques and products to control hospital infection rates and break the chain of transmission of bacteria in clinical settings</li>
<li>Exploratory work into developing low-cost technologies to remove antibiotics and associated chemicals from effluents</li>
</ul>
<h3>We will NOT consider funding for:</h3>
<ul>
<li>Proposals to develop diagnostic devices and technologies or for drug discovery. Although diagnostic devices and new drugs are potentially critical to AMR solutions, these areas are not unique to AMR challenges and should therefore be advanced more comprehensively against a broader landscape of possible needs and solutions. Thus, while excluded here, they may be part of a future request for proposals.</li>
<li>Proposals without a clear application to surveillance or facilitating the development of new evidence describing the global burden of AMR</li>
<li>Proposals seeking to apply existing tools in ways that do not transform our understanding of the global emergence or spread of AMR</li>
<li>Incremental improvements to conventional solutions or typical disease surveillance. We will not consider local surveillance programs or projects or small improvements in surveillance, e.g., use of mobile data collection, automation of traditional processes, or improving access to existing tools or technologies.</li>
<li>Proposals that simply expand the availability of primary data without a clear link to informing our understanding of global AMR epidemiology</li>
<li>Applications proposing basic research</li>
<li>Ideas not directly relevant to low- and middle-income contexts</li>
<li>Genomic and other laboratory-based approaches that lack a clear application to AMR surveillance or epidemiology</li>
<li>Ideas focused on quantifying resistance in animal or livestock populations or in environmental samples without a direct linkage to how data would impact public health practice</li>
<li>Proposals involving clinical trials in human volunteers or patients (note: use of existing datasets or other outputs from clinical trials may be considered, as long as the proposed approach is feasible within the time and financial envelopes provided).</li>
</ul>

We seek new approaches that have the potential to transform public health action on a regional or global scale by identifying and filling gaps in knowledge on the burden of resistance to antibacterial agents, including the linking together of different research communities for new perspectives on the problem.

Grand Challenges South Africa New Approaches to Characterize the Global Burden of Antimicrobial Resistance

This challenge focuses on new measurement tools and new combinations of approaches to ensure all children thrive – that they not only survive, but also have the chance to live healthy productive lives.&nbsp; The ultimate goal of this challenge is to determine what packages of interventions should be delivered to which group of individuals at what point in their life cycle to reduce the burden of fetal growth impairment and preterm birth, stunted postnatal growth, and impaired cognitive development.This challenge joins the All Children Thriving platform, which links Grand Challenges programs targeting healthy birth, growth, and development, including the global programs <a href="http://www.grandchallenges.ca/saving-brains/" target="_blank">Saving Brains</a> and <a href="http://savinglivesatbirth.net/" target="_blank">Saving Lives at Birth</a> and a set of four new programs launched concurrently. These new programs are <a href="https://gcgh.grandchallenges.org/challenge/all-children-thriving-brazil" target="_blank">Grand Challenges Brazil: All Children Thriving</a>; <a href="http://gcgh.grandchallenges.org/challenge/all-children-thriving-0" target="_blank">Grand Challenges India: All Children Thriving</a>; Grand Challenges South Africa: All Children Thriving; and <a href="http://gcgh.grandchallenges.org/challenge/creating-and-measuring-integrated-solutions-healthy-birth-growth-and-development" target="_blank">Creating and Measuring Integrated Solutions for Healthy Birth, Growth, and Development</a> (a global program with awards to investigators in low- and middle-income countries).